Midodrine (Midodrine Hydrochloride)

Midodrine, the active ingredient in Midodrine, is an Alpha-1 adrenergic agonist presented as an oral tablet for systemic use. It increases peripheral vascular resistance, thereby raising blood pressure in adults diagnosed with orthostatic hypotension, helping to prevent dizziness and fainting.

GNH USA supplies Midodrine as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing, regulatory support and consistent product quality for healthcare providers seeking an antihypotensive agent through established distribution networks and competitive pricing.

Midodrine is used to manage conditions related to low blood pressure, particularly orthostatic hypotension.

- Orthostatic hypotension: Improves standing blood pressure and reduces symptoms such as dizziness or syncope. - Neurogenic orthostatic hypotension: Increases vascular tone in patients with autonomic failure, helping maintain cerebral perfusion. - Post‑ural hypotension (e.g., after prolonged bed rest): Supports blood pressure stability when transitioning to upright position.

Midodrine may be associated with several adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Piloerection (goose‑flesh): mild skin reaction. - Pruritus: itching, often localized. - Urinary retention: difficulty emptying bladder. - Supine hypertension: elevated blood pressure while lying down. - Nausea: mild gastrointestinal upset. - Headache: transient cranial discomfort.

Serious or Rare Side Effects: - Severe supine hypertension: marked increase in blood pressure requiring medical intervention. - Cardiac arrhythmias: irregular heart rhythms that may be life‑threatening. - Ischemic events: reduced blood flow leading to tissue injury, such as peripheral ischemia.

When prescribing Midodrine, clinicians should consider several precautionary measures to ensure safe use.

- Cardiovascular assessment: evaluate for pre‑existing hypertension before initiating therapy. - Supine positioning: advise patients to remain upright for at least 4 hours after dosing to minimize supine hypertension. - Renal impairment: adjust monitoring in patients with severe kidney dysfunction. - Concomitant antihypertensives: review other blood‑pressure‑lowering agents to avoid excessive hypotension. - Pregnancy and lactation: use only if potential benefit justifies potential risk, as safety data are limited. - Store at ambient temperature: keep tablets below 25 °C in the original container, protected from moisture and light.

Midodrine can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): combined use may cause excessive vasoconstriction and hypertensive crisis. - Direct vasopressors (e.g., norepinephrine): additive pressor effects can lead to severe hypertension.

Moderate Interactions (Monitor Closely): - Antihypertensive agents (ACE inhibitors, beta‑blockers, diuretics): may blunt the intended blood‑pressure‑raising effect. - Diuretics: can exacerbate volume depletion, increasing risk of orthostatic symptoms. - Tricyclic antidepressants: may potentiate α‑adrenergic stimulation. - Central nervous system depressants: monitor for dizziness as blood pressure changes.